These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 6548211

  • 21. Dual-function radiation sensitizers and bioreductive drugs: factors affecting cellular uptake and sensitizing efficiency in analogues of RSU 1069.
    Walling J, Stratford IJ, Adams GE, Stephens MA.
    Int J Radiat Biol Relat Stud Phys Chem Med; 1988 Apr; 53(4):641-9. PubMed ID: 3258298
    [Abstract] [Full Text] [Related]

  • 22. Radiosensitizing and cytotoxic effects of nitroimidazoles in CHO cells expressing elevated levels of glutathione-S-transferase.
    Stratford IJ, Hickson ID, Robson CN, Stephens M.
    Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1307-10. PubMed ID: 2523884
    [Abstract] [Full Text] [Related]

  • 23. Cytotoxicity of RSU 1069 in spheroids and murine tumors.
    Olive PL, Durand RE, Chaplin DJ.
    Int J Radiat Oncol Biol Phys; 1987 Sep; 13(9):1361-6. PubMed ID: 3624045
    [Abstract] [Full Text] [Related]

  • 24. Time scale of radiation damage by 2,4-dinitrophenyl-aziridine (CB 1954) in Chinese hamster cells: a rapid-mix study.
    Kandaiya S.
    Int J Radiat Biol Relat Stud Phys Chem Med; 1985 Sep; 48(3):441-6. PubMed ID: 3875583
    [Abstract] [Full Text] [Related]

  • 25. Postirradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers.
    Chaplin DJ.
    Radiat Res; 1988 Aug; 115(2):292-302. PubMed ID: 3406369
    [Abstract] [Full Text] [Related]

  • 26. Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).
    Chaplin DJ.
    Br J Cancer; 1986 Nov; 54(5):727-31. PubMed ID: 3801269
    [Abstract] [Full Text] [Related]

  • 27. Studies with bifunctional bioreductive drugs. II. Cytotoxicity assayed with A-549 lung carcinoma cells of human origin.
    Roizin-Towle L, Pirro JP, Hall EJ.
    Radiat Res; 1990 Oct; 124(1 Suppl):S50-5. PubMed ID: 2236511
    [Abstract] [Full Text] [Related]

  • 28. A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.
    Suto MJ, Stier MA, Werbel LM, Arundel-Suto CM, Leopold WR, Elliott WE, Sebolt-Leopold JS.
    J Med Chem; 1991 Aug; 34(8):2484-8. PubMed ID: 1875345
    [Abstract] [Full Text] [Related]

  • 29. Experimental pharmacokinetics of RSU-1069 and its analogues: high tumor/plasma ratios.
    Deacon JM, Holliday SB, Ahmed I, Jenkins TC.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1087-90. PubMed ID: 3755713
    [Abstract] [Full Text] [Related]

  • 30. Cytocidal effects of misonidazole, Ro 03-8799, and RSU-1164 on euoxic and hypoxic BP-8 murine sarcoma cells at normal and elevated temperatures.
    Hofer KG, Lakkis M, Hofer MG.
    Cancer; 1989 Apr 15; 63(8):1501-8. PubMed ID: 2924258
    [Abstract] [Full Text] [Related]

  • 31. Oncogenic transforming potential of nitroimidazole radiosensitizers.
    Hall EJ, Hei TK.
    Int J Radiat Oncol Biol Phys; 1989 May 15; 16(5):1231-4. PubMed ID: 2523882
    [Abstract] [Full Text] [Related]

  • 32. Chemopotentiation by CB 1954: the importance of postincubations and the possible involvement of poly(ADP-ribosylation).
    Walling JM, Stratford IJ, Stephens MA.
    Int J Radiat Oncol Biol Phys; 1984 Sep 15; 10(9):1661-4. PubMed ID: 6434498
    [Abstract] [Full Text] [Related]

  • 33. In vitro assessment of the oncogenic potential of nitroimidazole radiosensitizers.
    Hei TK, Geard CR, Osmak RS, Hall EJ.
    Int J Radiat Oncol Biol Phys; 1985 Sep 15; 11(9):1653-8. PubMed ID: 3839777
    [Abstract] [Full Text] [Related]

  • 34. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.
    Chaplin DJ, Acker B.
    Int J Radiat Oncol Biol Phys; 1987 Apr 15; 13(4):579-85. PubMed ID: 3558048
    [Abstract] [Full Text] [Related]

  • 35. Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice.
    Kanclerz A, Chapman JD.
    Int J Radiat Oncol Biol Phys; 1988 Feb 15; 14(2):309-16. PubMed ID: 2828290
    [Abstract] [Full Text] [Related]

  • 36. Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapy.
    Henry JM, Isaacs JT.
    J Urol; 1989 Jul 15; 142(1):165-70. PubMed ID: 2733098
    [Abstract] [Full Text] [Related]

  • 37. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
    Cole S, Stratford IJ, Fielden EM, Adams GE, Leopold W, Elliott W, Suto M, Sebolt-Leopold J.
    Int J Radiat Oncol Biol Phys; 1992 Jul 15; 22(3):545-8. PubMed ID: 1735694
    [Abstract] [Full Text] [Related]

  • 38. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
    Cole S, Stratford IJ, Bowler J, Nolan J, Wright EG, Lorimore SA, Adams GE.
    Int J Radiat Oncol Biol Phys; 1991 Jul 15; 21(2):387-95. PubMed ID: 2061115
    [Abstract] [Full Text] [Related]

  • 39. Induction of DNA crosslinks in vitro upon reduction of the nitroimidazole-aziridines RSU-1069 and RSU-1131.
    O'Neill P, McNeil SS, Jenkins TC.
    Biochem Pharmacol; 1987 Jun 01; 36(11):1787-92. PubMed ID: 3579973
    [Abstract] [Full Text] [Related]

  • 40. Studies with bifunctional bioreductive drugs. I. In vitro oncogenic transforming potential.
    Hei TK, He ZY, Piao CQ, Hall EJ.
    Radiat Res; 1990 Oct 01; 124(1 Suppl):S44-9. PubMed ID: 2236509
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.